No plasmatic proteomic signature at clinical disease onset associated with 11 year clinical, cognitive and MRI outcomes in relapsing-remitting multiple sclerosis patients

Claire Bridel; Anand J.C. Eijlers; Wessel N. van Wieringen; Marleen Koel-Simmelink; Cyra E. Leurs; Menno M. Schoonheim; Joep Killestein; Charlotte E. Teunissen

doi:10.3389/fnmol.2018.00371

No plasmatic proteomic signature at clinical disease onset associated with 11 year clinical, cognitive and MRI outcomes in relapsing-remitting multiple sclerosis patients

Claire Bridel^*, Anand J.C. Eijlers, Wessel N. van Wieringen, Marleen Koel-Simmelink, Cyra E. Leurs, Menno M. Schoonheim, Joep Killestein, Charlotte E. Teunissen

^*Corresponding author for this work

Research output: Contribution to Journal › Article › Academic › peer-review

Abstract

Background: The clinical course of relapsing-remitting multiple sclerosis (RRMS) is highly heterogeneous and prognostic biomarkers at time of diagnosis are lacking. Objective: We investigated the predictive value of the plasma proteome at time of diagnosis in RRMS patients. Methods: The plasma proteome was interrogated using a novel aptamer-based proteomics platform, which allows to measure the levels of a predefined set of 1310 proteins. Results: In 67 clinically and radiologically well characterized RRMS patients, we found no association between the plasma proteome at diagnosis and clinical, cognitive or MRI outcomes after 11 years. Conclusions: Proteomics studies on cerebrospinal fluid may be better suited to identify prognostic biomarkers in early RRMS.

Original language	English
Article number	371
Pages (from-to)	1-6
Number of pages	6
Journal	Frontiers in Molecular Neuroscience
Volume	11
DOIs	https://doi.org/10.3389/fnmol.2018.00371
Publication status	Published - 31 Oct 2018

Funding

This research was supported by the Swiss MS Society to CB and by grants from the Dutch MS Research Foundation (Grant No. 14-358e) to AE.

Funders	Funder number
Dutch MS Research Foundation	14-358e
Swiss MS Society

Keywords

Cognition
MRI
Multiple sclerosis
Prognosis
Proteomics

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3389/fnmol.2018.00371

Persistent URL (handle)

Persistent link

Cite this

Bridel, C., Eijlers, A. J. C., van Wieringen, W. N., Koel-Simmelink, M., Leurs, C. E., Schoonheim, M. M., Killestein, J., & Teunissen, C. E. (2018). No plasmatic proteomic signature at clinical disease onset associated with 11 year clinical, cognitive and MRI outcomes in relapsing-remitting multiple sclerosis patients. Frontiers in Molecular Neuroscience, 11, 1-6. Article 371. https://doi.org/10.3389/fnmol.2018.00371

@article{067aaa68390a4c75bcf22287db54d626,

title = "No plasmatic proteomic signature at clinical disease onset associated with 11 year clinical, cognitive and MRI outcomes in relapsing-remitting multiple sclerosis patients",

abstract = "Background: The clinical course of relapsing-remitting multiple sclerosis (RRMS) is highly heterogeneous and prognostic biomarkers at time of diagnosis are lacking. Objective: We investigated the predictive value of the plasma proteome at time of diagnosis in RRMS patients. Methods: The plasma proteome was interrogated using a novel aptamer-based proteomics platform, which allows to measure the levels of a predefined set of 1310 proteins. Results: In 67 clinically and radiologically well characterized RRMS patients, we found no association between the plasma proteome at diagnosis and clinical, cognitive or MRI outcomes after 11 years. Conclusions: Proteomics studies on cerebrospinal fluid may be better suited to identify prognostic biomarkers in early RRMS.",

keywords = "Cognition, MRI, Multiple sclerosis, Prognosis, Proteomics",

author = "Claire Bridel and Eijlers, {Anand J.C.} and {van Wieringen}, {Wessel N.} and Marleen Koel-Simmelink and Leurs, {Cyra E.} and Schoonheim, {Menno M.} and Joep Killestein and Teunissen, {Charlotte E.}",

year = "2018",

month = oct,

day = "31",

doi = "10.3389/fnmol.2018.00371",

language = "English",

volume = "11",

pages = "1--6",

journal = "Frontiers in Molecular Neuroscience",

issn = "1662-5099",

publisher = "Frontiers Media SA",

}

Bridel, C, Eijlers, AJC, van Wieringen, WN, Koel-Simmelink, M, Leurs, CE, Schoonheim, MM, Killestein, J & Teunissen, CE 2018, 'No plasmatic proteomic signature at clinical disease onset associated with 11 year clinical, cognitive and MRI outcomes in relapsing-remitting multiple sclerosis patients', Frontiers in Molecular Neuroscience, vol. 11, 371, pp. 1-6. https://doi.org/10.3389/fnmol.2018.00371

No plasmatic proteomic signature at clinical disease onset associated with 11 year clinical, cognitive and MRI outcomes in relapsing-remitting multiple sclerosis patients. / Bridel, Claire; Eijlers, Anand J.C.; van Wieringen, Wessel N. et al.
In: Frontiers in Molecular Neuroscience, Vol. 11, 371, 31.10.2018, p. 1-6.

Research output: Contribution to Journal › Article › Academic › peer-review

TY - JOUR

T1 - No plasmatic proteomic signature at clinical disease onset associated with 11 year clinical, cognitive and MRI outcomes in relapsing-remitting multiple sclerosis patients

AU - Bridel, Claire

AU - Eijlers, Anand J.C.

AU - van Wieringen, Wessel N.

AU - Koel-Simmelink, Marleen

AU - Leurs, Cyra E.

AU - Schoonheim, Menno M.

AU - Killestein, Joep

AU - Teunissen, Charlotte E.

PY - 2018/10/31

Y1 - 2018/10/31

N2 - Background: The clinical course of relapsing-remitting multiple sclerosis (RRMS) is highly heterogeneous and prognostic biomarkers at time of diagnosis are lacking. Objective: We investigated the predictive value of the plasma proteome at time of diagnosis in RRMS patients. Methods: The plasma proteome was interrogated using a novel aptamer-based proteomics platform, which allows to measure the levels of a predefined set of 1310 proteins. Results: In 67 clinically and radiologically well characterized RRMS patients, we found no association between the plasma proteome at diagnosis and clinical, cognitive or MRI outcomes after 11 years. Conclusions: Proteomics studies on cerebrospinal fluid may be better suited to identify prognostic biomarkers in early RRMS.

AB - Background: The clinical course of relapsing-remitting multiple sclerosis (RRMS) is highly heterogeneous and prognostic biomarkers at time of diagnosis are lacking. Objective: We investigated the predictive value of the plasma proteome at time of diagnosis in RRMS patients. Methods: The plasma proteome was interrogated using a novel aptamer-based proteomics platform, which allows to measure the levels of a predefined set of 1310 proteins. Results: In 67 clinically and radiologically well characterized RRMS patients, we found no association between the plasma proteome at diagnosis and clinical, cognitive or MRI outcomes after 11 years. Conclusions: Proteomics studies on cerebrospinal fluid may be better suited to identify prognostic biomarkers in early RRMS.

KW - Cognition

KW - MRI

KW - Multiple sclerosis

KW - Prognosis

KW - Proteomics

UR - http://www.scopus.com/inward/record.url?scp=85056709022&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056709022&partnerID=8YFLogxK

U2 - 10.3389/fnmol.2018.00371

DO - 10.3389/fnmol.2018.00371

M3 - Article

AN - SCOPUS:85056709022

SN - 1662-5099

VL - 11

SP - 1

EP - 6

JO - Frontiers in Molecular Neuroscience

JF - Frontiers in Molecular Neuroscience

M1 - 371

ER -

No plasmatic proteomic signature at clinical disease onset associated with 11 year clinical, cognitive and MRI outcomes in relapsing-remitting multiple sclerosis patients

Abstract

Funding

Keywords

UN SDGs

Access to Document

Persistent URL (handle)

Other files and links

Fingerprint

Cite this